Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Drops By 11.0%

Bio-Path Holdings, Inc. (NASDAQ:BPTHGet Rating) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 42,800 shares, a decline of 11.0% from the August 15th total of 48,100 shares. Approximately 2.5% of the shares of the stock are sold short. Based on an average trading volume of 29,900 shares, the days-to-cover ratio is currently 1.4 days.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $3.65 on Wednesday. The business’s 50 day moving average price is $3.82 and its 200 day moving average price is $3.59. The company has a market cap of $26.13 million, a price-to-earnings ratio of -2.06 and a beta of 1.45. Bio-Path has a one year low of $2.68 and a one year high of $5.48.

Bio-Path (NASDAQ:BPTHGet Rating) last posted its quarterly earnings results on Tuesday, August 16th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.08. During the same period in the previous year, the business posted ($0.26) EPS. On average, analysts predict that Bio-Path will post -1.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Renaissance Technologies LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTHGet Rating) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 18,000 shares of the company’s stock, valued at approximately $70,000. Renaissance Technologies LLC owned 0.25% of Bio-Path as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 5.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, initiated coverage on shares of Bio-Path in a research note on Sunday. They set a “sell” rating for the company.

Bio-Path Company Profile

(Get Rating)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.